Taiwan Liposome Company Ltd. (TLC) and Exelixis Inc. (NASDAQ:EXEL) Comparison side by side

Taiwan Liposome Company Ltd. (NASDAQ:TLC) and Exelixis Inc. (NASDAQ:EXEL) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Taiwan Liposome Company Ltd. 6 0.00 N/A -0.51 0.00
Exelixis Inc. 22 6.72 N/A 2.08 10.22

Table 1 demonstrates Taiwan Liposome Company Ltd. and Exelixis Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Taiwan Liposome Company Ltd. 0.00% 0% 0%
Exelixis Inc. 0.00% 59.6% 53.1%

Analyst Ratings

Taiwan Liposome Company Ltd. and Exelixis Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Taiwan Liposome Company Ltd. 0 0 0 0.00
Exelixis Inc. 0 2 2 2.50

Competitively the average target price of Exelixis Inc. is $30.75, which is potential 52.30% upside.

Insider & Institutional Ownership

Roughly 2.46% of Taiwan Liposome Company Ltd. shares are held by institutional investors while 80.9% of Exelixis Inc. are owned by institutional investors. On the other hand, insiders held about 1.4% of Exelixis Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Taiwan Liposome Company Ltd. -2.37% -4.63% -11.97% -21.97% 0% -6.36%
Exelixis Inc. 2.7% -1.07% 9.98% -8.71% -0.93% 8.13%

For the past year Taiwan Liposome Company Ltd. had bearish trend while Exelixis Inc. had bullish trend.


Exelixis Inc. beats Taiwan Liposome Company Ltd. on 9 of the 9 factors.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The companyÂ’s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.